Alchemia's HA-irinotecan remains on track for mCRC
This article was originally published in Scrip
The Australian company Alchemia has received independent data safety monitoring board approval to continue its pivotal multinational Phase III program with a modified formulation of irinotecan for metastatic colorectal cancer (mCRC).
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.